Malignant Neoplasm of Prostate
8
3
4
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate Cancer
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial
Single-Port Versus Multi-Port Robotic Radical Prostatectomy
68Ga-AAZTA-093 PET/CT: First-in-human Study
Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease
Hypofractionated Radiation Therapy in Prostate Cancer